Please note that the company has been acquired.
We thank all the patients who have supported us throughout this journey, as well as the scientific researchers, clinicians, and collaborators whose dedication and contributions have made this work possible. However, our commitment to you continues, as such we continue to monitor the following communication channels.
Legacy clinical data: legacy@rytolscience.com
Active trial transitions: trials@rytolscience.com
Human resources and staff support: HR@rytolscience.com
A legacy of oncology discovery.
Following the successful acquisition of our therapeutic pipeline, clinical operations and asset development have transitioned to global integration. This portal serves as the definitive legal and operational archive for all legacy activities.
Our commitment to oncology research has culminated in a transition designed to scale our therapeutic candidates globally. All ongoing clinical trials are being integrated under the new global parent organization.
The therapeutic platform.
Our proprietary oncology platform targeted critical pathways in solid tumors. The complete record of our preclinical milestones, molecular data, and clinical trial results remains preserved for researchers and partners.
Operational transition channels.
Please select the appropriate channel below for clinical data, active trials, or administrative inquiries.
Legacy Records
Trial Transitions
Corporate Inquiries
Access historical clinical trial data, patient registries, and molecular research documentation.
Guidelines and direct contacts for active clinical investigators managing ongoing patient cohorts.
Contact information for the integration office, shareholder relations, and administrative transitions.
Access the directory.
Find the verified contact channels, email directories, and instructions for legacy clinical trials, medical inquiries, and administrative offices.